UBS Group’s Scopus BioPharma Inc. Common Stock SCPS Stock Holding History

UBS Group’s Portfolio SCPS Stock Details SCPS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,254	Closed	-$1K	–	11671
2022 Q3	$1K	Buy	2,254 +2,154	+2,154%	+$782	﹤0.01%	10226
2022 Q2	$0	Hold	100	–	–	﹤0.01%	11502
2022 Q1	$0	Sell	100 -4,740	-98%	-$4.58K	﹤0.01%	11377
2021 Q4	$8K	Buy	4,840 +4,740	+4,740%	+$14.4K	﹤0.01%	9107
2021 Q3	$0	Sell	100 -5,355	-98%	-$27.6K	﹤0.01%	10455
2021 Q2	$39K	Buy	5,455 +2,644	+94%	+$18.8K	﹤0.01%	6680
2021 Q1	$24K	Buy	+2,811	New	+$29.4K	﹤0.01%	7222

Other funds holding SCPS

MRCM

M&R Capital Management Summit, New Jersey $454M AUM 40.11% 1-Year Est. Return

UBS Group's SCPS Position: Q4 2022 in Review

UBS Group sold out of Scopus BioPharma Inc. Common Stock (SCPS) in Q4 2022, closing a stake of 2,254 shares — an estimated $1K sold.

UBS Group first reported a position in SCPS in Q1 2021 and held it in 7 quarters. The position peaked at $39K in Q2 2021. 1 fund tracked by Wall St. Rank holds SCPS as of Q4 2022.

UBS Group reported no remaining Scopus BioPharma Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
UBS Group sold 2,254 Scopus BioPharma Inc. Common Stock shares in Q4 2022, an estimated $1K.
UBS Group first reported a position in Scopus BioPharma Inc. Common Stock in Q1 2021 and held it in 7 quarters.
UBS Group's Scopus BioPharma Inc. Common Stock position peaked at $39K in Q2 2021.
1 fund tracked by Wall St. Rank held Scopus BioPharma Inc. Common Stock as of Q4 2022.

Based on UBS Group's 13F filing for Q4 2022, filed 8 Feb 2023.